Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy vs androgen deprivation therapy in AR-positive recurrent/metastatic salivary gland cancer
2013-000314-38Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bicalutamide, triptorelin, cisplatin, doxorubicin, carboplatin and 1 more in salivary gland cancer (SGC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Primary endpoint in treatment-naïve cohort (Cohort A). Started Apr 2014; status: completed.
02
Drugs
bicalutamidetriptorelincisplatindoxorubicincarboplatin
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on 2013-000314-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000314-38.